Skip to Main Content

Author Details

Michael Peyton
Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center
1994
67
46
PMIDPaper TitleJournal TitlePublished Year
37398419ASCL1-ERK1/2 Axis: ASCL1 restrains ERK1/2 via the dual specificity phosphatase DUSP6 to promote survival of a subset of neuroendocrine lung cancers.bioRxiv2023
35492873AXL targeting restores PD-1 blockade sensitivity of <i>STK11/LKB1</i> mutant NSCLC through expansion of TCF1<sup>+</sup> CD8 T cells.Cell Rep Med2022
34301758Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations.Cancer Res2021
32512502An in vivo functional genomics screen of nuclear receptors and their co-regulators identifies FOXA1 as an essential gene in lung tumorigenesis.Neoplasia2020
31948943SLC43A3 Is a Biomarker of Sensitivity to the Telomeric DNA Damage Mediator 6-Thio-2'-Deoxyguanosine.Cancer Res2020
33269343EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer.Nat Cancer2020
32984844eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer.Nat Cancer2020
30615629Elucidating synergistic dependencies in lung adenocarcinoma by proteome-wide signaling-network analysis.PLoS One2019
29681454Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer.Cell2018
30015158Telomerase-Mediated Strategy for Overcoming Non-Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance.Neoplasia2018
29613856TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer.J Clin Invest2018
27821484PROTOCADHERIN 7 Acts through SET and PP2A to Potentiate MAPK Signaling by EGFR and KRAS during Lung Tumorigenesis.Cancer Res2017
28102363SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers.Nat Commun2017
26755624Computational discovery of pathway-level genetic vulnerabilities in non-small-cell lung cancer.Bioinformatics2016
28881577A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas.Oncotarget2016
27960087Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.Cancer Cell2016
27192120Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.Oncotarget2016
26069186Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.Cancer Discov2015
24297535Integrative analysis of two cell lines derived from a non-small-lung cancer patient--a panomics approach.Pac Symp Biocomput2014
23091115An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.Clin Cancer Res2013
24243015Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer.Cell2013
24166906Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial.Clin Cancer Res2013
24034250EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance.Cell2013
23724988Distinct transcriptome profiles identified in normal human bronchial epithelial cells after exposure to γ-rays and different elemental particles of high Z and energy.BMC Genomics2013
22158273Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide.Br J Cancer2012
22961666Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.Cancer Discov2012
22933705Stromal platelet-derived growth factor receptor α (PDGFRα) provides a therapeutic target independent of tumor cell PDGFRα expression in lung cancer xenografts.Mol Cancer Ther2012
21444672STAT3 mediates resistance to MEK inhibitor through microRNA miR-17.Cancer Res2011
22049529SMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner.Cancer Res2011
21899495Direct sequencing in cytological specimens as a useful strategy for detecting EGFR mutations in non-small cell lung cancer patients.Clin Chem Lab Med2011
21306997Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.Mol Cancer Ther2011
19708690MRI-visible micellar nanomedicine for targeted drug delivery to lung cancer cells.Mol Pharm2010
21124782Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.PLoS One2010
20489150Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis.Am J Pathol2010
20547836Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression.Proc Natl Acad Sci U S A2010
20663904Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation.Cancer Res2010
19904222Protection against chronic pancreatitis and pancreatic fibrosis in mice overexpressing pancreatic secretory trypsin inhibitor.Pancreas2010
19262564SRBC/cavin-3 is a caveolin adapter protein that regulates caveolae function.EMBO J2009
19351834PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.Cancer Res2009
19451690Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.J Clin Invest2009
19179890Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines.J Thorac Oncol2009
19117057MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors.Int J Cancer2009
19238210Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.PLoS One2009
18423824Implications of EGFR inhibition in ovarian cancer cell proliferation.Gynecol Oncol2008
17429401Synthetic lethal screen identification of chemosensitizer loci in cancer cells.Nature2007
17996648Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis.Cancer Cell2007
16489012Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.Cancer Res2006
17018617Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation.Cancer Res2006
16843264Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.Cancer Cell2006
15765407Transgenic expression of pancreatic secretory trypsin inhibitor-I ameliorates secretagogue-induced pancreatitis in mice.Gastroenterology2005
  • 1 - 50 of 67

Recommended Authors

Margaret Soucheray
J. David Gladstone Institutes
Career Start Year 2012
Number of shared co-authors 2
Sandra Cristea
Stanford University
Career Start Year 2011
Number of shared co-authors 2
Yisong Wang
Lombardi Comprehensive Cancer Center, Georgetown University
Career Start Year 2010
Number of shared co-authors 0
Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 0
John T Poirier
Laura and Isaac Perlmutter Cancer Center
Career Start Year 2007
Number of shared co-authors 5
Aik Choon Tan
Huntsman Cancer Institute, The University of Utah
Career Start Year 2003
Number of shared co-authors 1
Ming Li
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2003
Number of shared co-authors 0
Elena Ivanova
Dana-Farber Cancer Institute
Career Start Year 2003
Number of shared co-authors 8
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 0
Jianjun Shen
The University of Texas MD Anderson Cancer Center
Career Start Year 1998
Number of shared co-authors 7
Nhu-An Pham
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1998
Number of shared co-authors 0
Collin M Blakely
University of California san francisco
Career Start Year 1998
Number of shared co-authors 6
Ni Liu
Princess Margaret Cancer Centre, University Health Network, University of Toronto
Career Start Year 1997
Number of shared co-authors 3
Dongquan Chen
University of Alabama at Birmingham
Career Start Year 1997
Number of shared co-authors 0
John D Gordan
Quantitative Biosciences Institute (QBI), University of California San Francisco
Career Start Year 1996
Number of shared co-authors 3
Peter S Hammerman
Novartis Institutes for BioMedical Research
Career Start Year 1996
Number of shared co-authors 15
Hai Hu
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Career Start Year 1996
Number of shared co-authors 4
Krister Wennerberg
University of Copenhagen
Career Start Year 1994
Number of shared co-authors 8
David N Watkins
Research Institute in Oncology and Hematology
Career Start Year 1991
Number of shared co-authors 4
E Alejandro Sweet-Cordero
University of California San Francisco
Career Start Year 1989
Number of shared co-authors 3
Todd R Golub
Broad Institute of MIT and Harvard
Career Start Year 1989
Number of shared co-authors 12
Charles M Rudin
Memorial Sloan Kettering Cancer Center
Career Start Year 1989
Number of shared co-authors 15
Wei Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 12
David S Schrump
Center for Cancer Research, National Cancer Institute
Career Start Year 1988
Number of shared co-authors 0
Rakesh Kumar
Rutgers New Jersey Medical School
Career Start Year 1987
Number of shared co-authors 6
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Career Start Year 1987
Number of shared co-authors 18
Andrew D Cherniack
Dana-Farber Cancer Institute
Career Start Year 1984
Number of shared co-authors 18
John A Copland
Mayo Clinic Jacksonville
Career Start Year 1982
Number of shared co-authors 0
Francisca Vazquez
Broad Institute of MIT and Harvard
Career Start Year 1979
Number of shared co-authors 9
Ming-Sound Tsao
University Health Network, University of Toronto
Career Start Year 1972
Number of shared co-authors 19

Collaborators

John D Minna
University of Texas Southwestern Medical Center at Dallas
Co-authored papers 49
Yang Xie
Quantitative Biomedical Research Center
Co-authored papers 9
Michael A White
University of Georgia
Co-authored papers 6
Roy S Herbst
Yale School of Medicine
Co-authored papers 5
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 4
Kevin R Coombes
Medical College of Georgia
Co-authored papers 4
Lixia Diao
The University of Texas MD Anderson Cancer Center
Co-authored papers 4
Wei Zhang
Montefiore Medical Center
Co-authored papers 3
Chao Xing
University of Texas Southwestern Medical Center
Co-authored papers 3
Scott M Lippman
Moores Cancer Center, university of california san diego
Co-authored papers 3
John N Weinstein
The University of Texas MD Anderson Cancer Center
Co-authored papers 3
Rahul K Kollipara
McDermott Center for Human Growth and Development.
Co-authored papers 3
Wan L Lam
British Columbia Cancer Research Institute
Co-authored papers 3
Young H Kim
Stanford University
Co-authored papers 3
Kimberley Avila
University of Texas Southwestern Medical Center
Co-authored papers 3
Jonathan R Pollack
Stanford University School of Medicine
Co-authored papers 3
Enrico Stefani
Co-authored papers 3
Hyun Seok Kim
Seoul National University
Co-authored papers 3
Ralf Kittler
McDermott Center for Human Growth and Development.
Co-authored papers 3
Matthew Meyerson
Broad Institute
Co-authored papers 2
David A Wheeler
Baylor College of Medicine
Co-authored papers 2
Paul Yenerall
McDermott Center for Human Growth and Development, UT Southwestern Medical Center
Co-authored papers 2
Barbara A Weir
Janssen Research and Development LLC
Co-authored papers 2
Martin L Sos
University of Cologne, Faculty of Medicine and University Hospital Cologne
Co-authored papers 2
Saurabh Mendiratta
University of Texas Southwestern Medical Center
Co-authored papers 2
Craig H Mermel
Co-authored papers 2
Levi A Garraway
Broad Institute of Harvard and MIT
Co-authored papers 2
Guanghua Xiao
The University of Texas Southwestern Medical Center
Co-authored papers 2
Robert Gentleman
Center for Computational Biomedicine, Harvard Medical School
Co-authored papers 1
Shannon K McWeeney
Oregon Health & Science University, University of California Berkeley
Co-authored papers 1
Release 1.2